The Anti-Cancer Effect of Pitavastatin May Be a Drug-Specific Effect: Subgroup Analysis of the TOHO-LIP Study.
The significance of statin treatment for the reduction of cardiovascular (CV) disease has been reported, whereas other reports have also described anti-cancer properties associated with the class effect of statins. However, the differences in anti-cancer effect of various types of statins have rarel...
| Publicado en: | Vascular Health & Risk Management Vol. 17; pp. 169 - 174 |
|---|---|
| Autores principales: | , , |
| Formato: | clinical trial research tables/charts Journal Article |
| Publicado: |
Dove Medical Press Ltd
Apr2021
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=150445172&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 150445172 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11766344 6BXM jtl: Vascular Health & Risk Management issn: 11766344 maglogo: N pubinfo: dt: Apr2021 vid: 17 pid: 45064 pub: Dove Medical Press Ltd place: Auckland, <Blank> artinfo: ui: 150445172 150445172 NLM33953560 150445172 10.2147/VHRM.S306540 NLM33953560 150445172 ppf: 169 ppct: 5 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: The Anti-Cancer Effect of Pitavastatin May Be a Drug-Specific Effect: Subgroup Analysis of the TOHO-LIP Study. aug: au: Nagayama, Daiji Saiki, Atsuhito Shirai, Kohji sug: subj: Neoplasms Prevention and Control Antineoplastic Agents Therapeutic Use Antilipemic Agents Therapeutic Use Quinolines Therapeutic Use Risk Factors Risk Assessment Antineoplastic Agents Adverse Effects Quinolines Adverse Effects Incidence Probability Clinical Trials Neoplasms Epidemiology Antilipemic Agents Adverse Effects Human ab: The significance of statin treatment for the reduction of cardiovascular (CV) disease has been reported, whereas other reports have also described anti-cancer properties associated with the class effect of statins. However, the differences in anti-cancer effect of various types of statins have rarely been examined. Pitavastatin is a statin with a different chemical structure and pharmacokinetics from other statins, and the mechanism of the specific anti-cancer effect of pitavastatin has been reported in in vivo therapeutic models. We previously revealed that pitavastatin therapy was superior to atorvastatin therapy in the prevention of CV events, despite similar LDL-cholesterol-lowering effect in the TOHO Lipid Intervention Trial Using Pitavastatin (TOHO-LIP). Furthermore, in subgroup analysis of the TOHO-LIP study, cumulative 240-week incidence of new cancer cases tended to be lower in the pitavastatin group compared to the atorvastatin group [0.32% (1/312) vs 1.94% (6/310), log-rank P=0.051]. This finding might reveal the superiority of pitavastatin to prevent carcinogenesis. The molecular mechanism by which pitavastatin suppresses the incidence of any-organ cancer is gradually elucidated, and new combination of cancer treatments with pitavastatin will be developed in the future to further enhance the anti-cancer activity and reduce the side effects. pubtype: Academic Journal doctype: clinical trial research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|